FIELD: medicine; pharmaceuticals.
SUBSTANCE: first object is a pharmaceutical composition for treating or preventing a cardiovascular disease, containing at least 95 % of ethyl-eicosapentaenoic acid (ethyl-EPA) encapsulated in capsule shell, which contains gelatine in amount of 50 to 70 wt %, glycerine in amount of 5 to 15 wt % and sorbitol in amount of 15 to 25 wt % and maltitol in amount of 3 to 10 wt % of the weight of the non-aqueous components. Second object is a method of treating or preventing diseases associated with cardiovascular system, comprising administering to a subject a therapeutically effective amount of the composition.
EFFECT: technical effect consists in weakening or preventing the oxidation of ethyl-EPA in the pharmaceutical composition, enclosed in the shell of the capsule according to the invention, to a greater extent than is provided by the standard capsule of type IIa.
8 cl, 3 dwg, 4 tbl, 4 ex
